{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:27:11Z","timestamp":1780439231761,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012433","name":"Key Project of Technological Innovation Application Development Plan of Chongqing City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017501","name":"Science Health Joint Medical Scientific Research Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jaad.2025.02.081","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:53:13Z","timestamp":1741002793000},"page":"415-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of prednisone plus either adalimumab or cyclosporine on dermatological symptoms in Vogt-Koyanagi-Harada disease: Systemic outcomes from a randomized trial"],"prefix":"10.1016","volume":"93","author":[{"given":"Zhenyu","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.02.081_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100866","article-title":"Activation of the interleukin-23\/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis","volume":"80","author":"Zhong","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.jaad.2025.02.081_bib2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10384-021-00850-8","article-title":"Prevalence and incidence rates and treatment patterns of non-infectious uveitis in Japan: real-world data using a claims database","volume":"65","author":"Umazume","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jaad.2025.02.081_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment","volume":"52","author":"Du","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jaad.2025.02.081_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajo.2016.06.004","article-title":"Outcomes of Vogt-Koyanagi-Harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies","volume":"168","author":"Shen","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jaad.2025.02.081_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/02713683.2017.1383444","article-title":"Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents","volume":"43","author":"Yang","year":"2018","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.jaad.2025.02.081_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10384-021-00878-w","article-title":"Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt-Koyanagi-Harada disease","volume":"66","author":"Ono","year":"2022","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.081_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/aos.13189","article-title":"Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease","volume":"95","author":"Abu El-Asrar","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jaad.2025.02.081_bib8","first-page":"1","article-title":"Efficacy and safety of adalimumab for exacerbation or relapse of ocular inflammation in patients with Vogt-Koyanagi-Harada disease: a multicenter study","volume":"24","author":"Nakai","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ophtha.2006.07.040","article-title":"Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients","volume":"114","author":"Yang","year":"2007","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ophtha.2009.08.030","article-title":"Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease","volume":"117","author":"Rao","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.081_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/09273948.2019.1668431","article-title":"Impact of inflammation and treatment on self-reported quality of life in patients with non-acute Vogt-Koyanagi-Harada disease (VKHD)","volume":"29","author":"Souto","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"10.1016\/j.jaad.2025.02.081_bib12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4103\/ijo.IJO_336_17","article-title":"Unusual case of vitiligo reversal in Vogt-Koyanagi-Harada syndrome","volume":"65","author":"Subudhi","year":"2017","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.081_bib13","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1186\/1869-5760-3-41","article-title":"Reversible alopecia in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia","volume":"3","author":"Chuang","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/archopthalmol.2011.1520","article-title":"Reversal of poliosis and vitiligo following Vogt-Koyanagi-Harada disease","volume":"130","author":"Tabbara","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.081_bib15","first-page":"023","article-title":"A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease","volume":"14","author":"Zhong","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jaad.2025.02.081_bib16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamaophthalmol.2018.2664","article-title":"Development and evaluation of diagnostic criteria for Vogt-Koyanagi-Harada disease","volume":"136","author":"Yang","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaad.2025.02.081_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ajo.2021.03.036","article-title":"Classification criteria for Vogt-Koyanagi-Harada disease","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/09273948.2016.1236969","article-title":"Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease","volume":"26","author":"Couto","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/09273948.2019.1603312","article-title":"Efficacy of adalimumab for chronic Vogt-Koyanagi-Harada disease refractory to conventional corticosteroids and immunosuppressive therapy and complicated by central serous chorioretinopathy","volume":"28","author":"Takayama","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5152\/eurjrheum.2017.160085","article-title":"Anti-TNF\u03b1 therapy and switching in severe uveitis related to Vogt-Koyanagi-Harada syndrome","volume":"4","author":"Flores-Robles","year":"2017","journal-title":"Eur J Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.081_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2025.02.081_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib23","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2665-9913(23)00030-9","article-title":"Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Patel","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.02.081_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10792-022-02440-0","article-title":"Outcomes of patients with acute Vogt-Koyanagi-Harada disease treated with intravenous corticosteroid pulse followed by the slow tapering of oral corticosteroid therapy","volume":"43","author":"Fushitsu","year":"2023","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/eye.2008.89","article-title":"Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease","volume":"23","author":"Lai","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.jaad.2025.02.081_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.705796","article-title":"New perspectives on the immunopathogenesis and treatment of uveitis associated with Vogt-Koyanagi-Harada disease","volume":"8","author":"Abu El-Asrar","year":"2021","journal-title":"Front Med"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.081_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4103\/JOCO.JOCO_190_20","article-title":"Vogt-Koyanagi-Harada is a curable autoimmune disease: early diagnosis and immediate dual steroidal and non-steroidal immunosuppression are crucial prerequisites","volume":"32","author":"Papasavvas","year":"2020","journal-title":"J Curr Ophthalmol"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.081_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4103\/sjopt.sjopt_204_22","article-title":"Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: a multicenter study","volume":"36","author":"Takeuchi","year":"2022","journal-title":"Saudi J Ophthalmol"},{"key":"10.1016\/j.jaad.2025.02.081_bib29","first-page":"1","article-title":"The steroid-sparing effect of adalimumab in the treatment for the recurrent phase of Vogt-Koyanagi-Harada disease","volume":"25","author":"Shinagawa","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.081_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/09273941003587541","article-title":"Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease","volume":"18","author":"Cuchacovich","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"issue":"16","key":"10.1016\/j.jaad.2025.02.081_bib31","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2025.02.081_bib32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for vitiligo: a systematic review and meta-analysis","volume":"153","author":"Bae","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.02.081_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.590558","article-title":"Case series: gene expression analysis in canine Vogt-Koyanagi-Harada\/uveodermatologic syndrome and vitiligo reveals conserved immunopathogenesis pathways between dog and human autoimmune pigmentary disorders","volume":"11","author":"Egbeto","year":"2020","journal-title":"Front Immunol"},{"issue":"2-3","key":"10.1016\/j.jaad.2025.02.081_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10792-006-9001-1","article-title":"The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey","volume":"27","author":"Tugal-Tutkun","year":"2007","journal-title":"Int Ophthalmol"},{"issue":"19","key":"10.1016\/j.jaad.2025.02.081_bib35","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 Years among patients with intermediate, posterior, or panuveitis","volume":"317","author":"Kempen","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jaad.2025.02.081_bib36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jaad.2025.02.081_bib37","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"10.1016\/j.jaad.2025.02.081_bib38","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225003718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225003718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T20:37:58Z","timestamp":1758659878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225003718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0190962225003718"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.081","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of prednisone plus either adalimumab or cyclosporine on dermatological symptoms in Vogt-Koyanagi-Harada disease: Systemic outcomes from a randomized trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}